Renovaro (NASDAQ:RENB) Releases Earnings Results

Renovaro (NASDAQ:RENB) posted its quarterly earnings data on Wednesday. The company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports.

Renovaro Stock Performance

RENB stock opened at $0.86 on Thursday. The company has a 50-day moving average of $0.94 and a two-hundred day moving average of $0.76. Renovaro has a 52-week low of $0.40 and a 52-week high of $3.38.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.